NCT04822337 - Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 19, 2021

Primary Completion Date

April 30, 2029

Study Completion Date

November 30, 2032

Conditions

Multiple Myeloma

Interventions

DRUG

Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin

Phase I - Chemotherapy multiple agents systemic Phase II - Maximum Tolerated Dose from Phase I

Trial Locations (2)

RECRUITING

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

RECRUITING

Levine Cancer Institute, Charlotte